CUAMC
China Universal Asset Management Company Portfolio holdings
AUM
$1.06B
1-Year Return
31.81%
This Quarter Return
+16%
1 Year Return
+31.81%
3 Year Return
+205.04%
5 Year Return
–
10 Year Return
–
AUM
$324M
AUM Growth
+$28.5M
(+9.6%)
Cap. Flow
-$70.4K
Cap. Flow
% of AUM
-0.02%
Top 10 Holdings %
Top 10 Hldgs %
32.96%
Holding
465
New
18
Increased
159
Reduced
244
Closed
13
Top Buys
| 1 |
Vanguard World Funds Extended Duration ETF
EDV
|
$3.28M |
| 2 |
Tesla
TSLA
|
$2.24M |
| 3 |
Apple
AAPL
|
$2.14M |
| 4 |
Meta Platforms (Facebook)
META
|
$2.1M |
| 5 |
Vaxcyte
PCVX
|
$2M |
Top Sells
| 1 |
iQIYI
IQ
|
$4.85M |
| 2 |
Amazon
AMZN
|
$4.7M |
| 3 |
Airbnb
ABNB
|
$3.2M |
| 4 |
Analog Devices
ADI
|
$2.94M |
| 5 |
KE Holdings
BEKE
|
$1.93M |
Sector Composition
| 1 | Technology | 41.8% |
| 2 | Consumer Discretionary | 21.38% |
| 3 | Healthcare | 19.26% |
| 4 | Communication Services | 6.74% |
| 5 | Financials | 4.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
276
Aurinia Pharmaceuticals
AUPH
$1.63B
| $18.2K | 0.01% |
1,875
-57
| -3% | -$552 |
|
277
89bio
ETNB
$1.32B
| $18.1K | 0.01% |
955
+270
| +39% | +$5.12K |
|
278
Recursion Pharmaceuticals
RXRX
$2.01B
| $18.1K | 0.01% |
2,420
-65
| -3% | -$486 |
|
279
IDEAYA Biosciences
IDYA
$2.38B
| $17.6K | 0.01% |
751
+99
| +15% | +$2.33K |
|
280
Replimune Group
REPL
$494M
| $17.6K | 0.01% |
757
-11
| -1% | -$255 |
|
281
BioCryst Pharmaceuticals
BCRX
$1.74B
| $17.4K | 0.01% |
2,477
-77
| -3% | -$542 |
|
282
Arvinas
ARVN
$575M
| $17.4K | 0.01% |
700
-22
| -3% | -$546 |
|
283
Kymera Therapeutics
KYMR
$3.11B
| $16.7K | 0.01% |
725
-23
| -3% | -$529 |
|
284
Ligand Pharmaceuticals
LGND
$3.25B
| $16.3K | 0.01% |
226
-5
| -2% | -$361 |
|
285
Repligen
RGEN
$7.01B
| $16.3K | 0.01% |
115
-2,841
| -96% | -$402K |
|
286
Merus
MRUS
$5.1B
| $16.1K | 0.01% |
610
-18
| -3% | -$474 |
|
287
ImmunityBio
IBRX
$2.27B
| $15.9K | ﹤0.01% |
5,715
+100
| +2% | +$278 |
|
288
Keros Therapeutics
KROS
$633M
| $15.6K | ﹤0.01% |
388
+15
| +4% | +$603 |
|
289
Twist Bioscience
TWST
$1.55B
| $15.3K | ﹤0.01% |
749
-21
| -3% | -$430 |
|
|
VERV
290
DELISTED
Verve Therapeutics
VERV
| $15.2K | ﹤0.01% |
812
-23
| -3% | -$431 |
|
291
Travere Therapeutics
TVTX
$1.93B
| $15K | ﹤0.01% |
978
+101
| +12% | +$1.55K |
|
292
Sana Biotechnology
SANA
$752M
| $15K | ﹤0.01% |
2,510
-74
| -3% | -$441 |
|
|
INBX
293
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $14.8K | ﹤0.01% |
572
-18
| -3% | -$467 |
|
|
DCPH
294
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $14.5K | ﹤0.01% |
1,029
| – | – |
|
295
ANI Pharmaceuticals
ANIP
$2.07B
| $14.3K | ﹤0.01% |
265
+29
| +12% | +$1.56K |
|
296
Lucid Motors
LCID
$5.66B
| $14.3K | ﹤0.01% |
207
+152
| +276% | +$10.5K |
|
297
MannKind Corp
MNKD
$1.7B
| $14.1K | ﹤0.01% |
3,464
-111
| -3% | -$452 |
|
298
Pliant Therapeutics
PLRX
$114M
| $14K | ﹤0.01% |
775
+2
| +0.3% | +$36 |
|
|
CBAY
299
DELISTED
Cymabay Therapeutics
CBAY
| $14K | ﹤0.01% |
1,278
-4
| -0.3% | -$44 |
|
|
AVDL
300
Avadel Pharmaceuticals
AVDL
$1.53B
| $13.9K | ﹤0.01% |
844
-7
| -0.8% | -$115 |
|